Screening people with Alzheimer's disease for possible future studies
Checks whether adults with Alzheimer's disease may qualify for later research studies.
Key facts
- Who runs it
- Hoffmann-La Roche
- Where
- Gwangju, Gyeonggi-do, Incheon, Namdong-gu, Seongnam-si, Seoul, and Suwon, South KoreaSee the 13 sitesAlso in 14 other countries, 221 sites
- Trial code
- Registry title
- Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 80,000 people, planned
- Started
- 2 Jul 2025
- Expected to end
- 31 Jul 2035
- Type of study
- Interventional
- Record updated
- 19 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
This is a pre-screening study. It checks whether people could join one of Roche's Alzheimer's disease trials, using biomarker tests and thinking tests.
- Age
- 50 Years to 90 Years
- Sex
- All sexes can join.
- Disease stage
- Alzheimer's disease. People with a clinical diagnosis of MCI or mild AD are named in the record.
- Biomarker or test result
- Biomarker status is checked. People with MCI or mild AD who already have a biomarker-confirmed AD diagnosis (amyloid PET, cerebrospinal fluid or blood biomarker) cannot join.
Main reasons for not taking part
- Needs help with basic daily activities because of memory or thinking problems
- Sight or hearing problems that stop the thinking tests (glasses and hearing aids are allowed)
- Another brain or nerve condition that may cause memory or thinking problems
- Severe head or brain injury with clinical significance in the past
- Serious medical condition that makes taking part in a study unsafe
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Ability and willingness to participate in an interventional clinical study, including meeting key eligibility criteria of linked interventional Roche AD studies (e.g., specific age ranges)
- Ability and willingness to receive information about potential eligibility in an associated interventional Roche AD study
Who cannot take part
- For participants with a clinical diagnosis of MCI or mild AD: Previous AD diagnosis based on biomarker confirmation with an approved or validated rule in method (e.g., amyloid PET or cerebrospinal fluid, blood biomarker) is exclusionary
- Dependency in basic activities of daily living (bADLs) due to cognitive impairment
- Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)
- Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
- History of severe, clinically significant central nervous system trauma
- Any serious medical condition that precludes a participant's safe participation and completion of a clinical study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 90 years old?
Where in South Korea
Also in 14 other countries, 221 sites
- Chonnam National University HospitalGwangju, South KoreaTaking people
- St. Vincent's HospitalGyeonggi-do, South KoreaNo longer taking part
- Inha University HospitalIncheon, South KoreaTaking people
- Gachon University Gil Medical CenterNamdong-gu, South KoreaTaking people
- Seoul National University Bundang HospitalSeongnam-si, South KoreaTaking people
- Asan Medical CenterSeoul, South KoreaTaking people
- Ewha Womans University Hospital (Seoul)Seoul, South KoreaTaking people
- Gangnam Severance HospitalSeoul, South KoreaTaking people
- Hanyang University Seoul HospitalSeoul, South KoreaTaking people
- Konkuk University Medical CenterSeoul, South KoreaTaking people
- Korea University Guro HospitalSeoul, South KoreaTaking people
- Samsung Medical CenterSeoul, South KoreaTaking people
- Ajou University Medical CenterSuwon, South KoreaTaking people
About the trial
What the trial wants to find out
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
The group in the trial
- Screening ArmOther group
Participants will be assessed for their concentration of pTau217 in blood and cognitive score in the International Shopping List Test (ISLT).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition
- Plain-language title
- Screening people with Alzheimer's disease for possible future studiesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07177352, who can take part
- Record updated
- 19 October 2026